Published in BMJ on September 23, 2005
Uncertainty in heterogeneity estimates in meta-analyses. BMJ (2007) 5.69
ASCOT: a tale of two treatment regimens. BMJ (2005) 1.56
EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol (2011) 0.95
Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis (2009) 0.91
The differential effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with respect to foot ulcer and limb amputation in those with diabetes. Wound Repair Regen (2010) 0.84
The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf (2015) 0.80
RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract (2013) 0.78
Angiotensin inhibition after myocardial infarction: does drug class matter? J Gen Intern Med (2006) 0.77
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag (2011) 0.76
Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction. Heart Vessels (2011) 0.75
Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection. Vasc Health Risk Manag (2010) 0.75
ASCOT: a tale of two treatment regimens: is ASCOT-BPLA being hyped-up? BMJ (2005) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst (1959) 94.48
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med (2001) 9.75
Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 8.77
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med (1992) 8.38
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet (1997) 7.46
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med (2004) 6.21
Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 5.42
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003) 4.91
The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med (1995) 4.61
Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med (2004) 3.96
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med (1992) 3.87
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens (2003) 2.24
Angiotensin receptor blockers and myocardial infarction. BMJ (2004) 2.02
Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. Am Heart J (2003) 1.50
Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation (2004) 1.42
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J (2000) 1.02
A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens (2002) 0.88
Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail (2003) 0.87
Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol (2002) 0.86
Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy. Diabetes Res Clin Pract (2004) 0.83
Does the addition of losartan improve the beneficial effects of ACE inhibitors in patients with anterior myocardial infarction? A pilot study. Heart (1999) 0.81
A comparison of intervention with losartan or captopril in acute myocardial infarction. Eur J Heart Fail (2000) 0.81
Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction. Heart (2001) 0.80
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT? Eur Heart J (2004) 0.80
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
A meta-analysis of the association between adherence to drug therapy and mortality. BMJ (2006) 7.79
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med (2008) 5.94
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care (2005) 4.78
Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med (2004) 4.72
Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet (2013) 4.58
Self-denigration in pharmacy: Words to banish from the pharmacy lexicon / Autodénigrement en pharmacie : mots à bannir du vocabulaire des pharmaciens. Can Pharm J (Ott) (2014) 4.19
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95
A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med (2008) 3.21
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care (2002) 3.12
Guidelines for pharmacists integrating into primary care teams. Can Pharm J (Ott) (2013) 3.05
Effect of fish oil on arrhythmias and mortality: systematic review. BMJ (2008) 2.76
Capturing outcomes of clinical activities performed by a rounding pharmacist practicing in a team environment: the COLLABORATE study [NCT00351676]. Med Care (2009) 2.56
Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ (2004) 2.55
Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med (2008) 2.55
Self-denigration in pharmacy: Actions that should be curtailed. Can Pharm J (Ott) (2014) 2.51
A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med (2002) 2.49
Does performance-based remuneration for individual health care practitioners affect patient care?: a systematic review. Ann Intern Med (2012) 2.35
Meta-analysis: cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med (2011) 2.34
Mortality and readmission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation (2011) 2.30
Pharmaceutical care in community pharmacies: practice and research in Canada. Ann Pharmacother (2005) 2.22
Collaboration between pharmacists, physicians and nurse practitioners: a qualitative investigation of working relationships in the inpatient medical setting. J Interprof Care (2009) 2.19
Validity and reliability of the Edmonton Frail Scale. Age Ageing (2006) 2.08
Stories from the trenches: Experiences of Alberta pharmacists in obtaining additional prescribing authority. Can Pharm J (Ott) (2012) 2.04
Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients. Circulation (2008) 1.98
Pharmacists' self-perception of their professional role: insights into community pharmacy culture. J Am Pharm Assoc (2003) (2011) 1.89
The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant (2009) 1.89
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ (2006) 1.80
The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol (2011) 1.78
Type 2 diabetes mellitus management in Canada: is it improving? Can J Diabetes (2013) 1.75
Enhancing primary care for complex patients. Demonstration project using multidisciplinary teams. Can Fam Physician (2004) 1.74
Impact of opinion leader-endorsed evidence summaries on the quality of prescribing for patients with cardiovascular disease: a randomized controlled trial. Am Heart J (2007) 1.73
Pharmacists' perceptions of their professional role: insights into hospital pharmacy culture. Can J Hosp Pharm (2011) 1.72
Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol (2007) 1.70
Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). J Am Coll Cardiol (2013) 1.70
Association between direct measures of body composition and prognostic factors in chronic heart failure. Mayo Clin Proc (2010) 1.63
Long-term association between frailty and health-related quality of life among survivors of critical illness: a prospective multicenter cohort study. Crit Care Med (2015) 1.62
HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol (2010) 1.60
The Enhancing Secondary Prevention in Coronary Artery Disease trial. CMAJ (2009) 1.57
Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med (2009) 1.56
Risk stratification schemes, anticoagulation use and outcomes: the risk--treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart (2011) 1.54
The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. Crit Care Med (2013) 1.52
The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. Eur Heart J (2009) 1.48
Relation of T-axis abnormalities to coronary artery disease and survival after cardiac catheterization. Am J Cardiol (2005) 1.48
Exploring the treatment-risk paradox in coronary disease. Arch Intern Med (2007) 1.48
Stroke prophylaxis in institutionalized elderly patients with atrial fibrillation. J Am Geriatr Soc (2004) 1.47
Pharmacist intervention for glycaemic control in the community (the RxING study). BMJ Open (2013) 1.45
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol (2012) 1.44
A systematic review of the evidence for pharmacist care of patients with dyslipidemia. Pharmacotherapy (2012) 1.42
Ontario pharmacists' crisis over Bill 16: A missed opportunity? Can Pharm J (Ott) (2012) 1.40
The misrepresentation of high drug costs: Who is looking out for the patient? Can Pharm J (Ott) (2017) 1.39
On becoming a new pharmacist. Can Pharm J (Ott) (2013) 1.38
Association between frailty and short- and long-term outcomes among critically ill patients: a multicentre prospective cohort study. CMAJ (2013) 1.35
Patterns of care and outcomes differ for urban versus rural patients with newly diagnosed heart failure, even in a universal healthcare system. Circ Heart Fail (2011) 1.35
Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care (2010) 1.31
Personality traits of hospital pharmacists: toward a better understanding of factors influencing pharmacy practice change. Can J Hosp Pharm (2013) 1.27
The relative importance of barriers to the prescription of warfarin for nonvalvular atrial fibrillation. Can J Cardiol (2003) 1.25
Resource use in the last 6 months of life among patients with heart failure in Canada. Arch Intern Med (2010) 1.23
Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician (2011) 1.17
Patient and informal caregivers' knowledge of heart failure: necessary but insufficient for effective self-care. Eur J Heart Fail (2009) 1.16
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Can J Cardiol (2008) 1.15
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest (2012) 1.14
Pharmacists' duty of care / Obligation de diligence du pharmacien. Can Pharm J (Ott) (2013) 1.12
Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. Open Med (2009) 1.12
A systematic review of patient self-reported barriers of adherence to antihypertensive medications using the world health organization multidimensional adherence model. J Clin Hypertens (Greenwich) (2012) 1.12
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. Int J Cardiol (2013) 1.11
Improving hypertension management through pharmacist prescribing; the rural Alberta clinical trial in optimizing hypertension (Rural RxACTION): trial design and methods. Implement Sci (2011) 1.11
Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study. Stroke (2007) 1.10
Reaffirming our focus on patient-centred care. Can Pharm J (Ott) (2015) 1.08
Publicly funded remuneration for the administration of injections by pharmacists: An international review. Can Pharm J (Ott) (2013) 1.08
Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials (2009) 1.05
Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol (2009) 1.04
Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail (2013) 1.04
Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail (2012) 1.02
Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review. Pediatrics (2010) 1.02
Carotid chemoreceptor modulation of blood flow during exercise in healthy humans. J Physiol (2011) 1.02
Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med (2010) 1.02
Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail (2012) 1.02
The expanding scope of pharmacists' practice: implications for physicians. CMAJ (2013) 1.01
Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail (2013) 1.01
Effect of a prior authorization process on antiplatelet therapy and outcomes in patients prescribed clopidogrel following coronary stenting. Can J Cardiol (2006) 1.01
Enhancing hypertension awareness and management in the elderly: lessons learned from the Airdrie Community Hypertension Awareness and Management Program (A-CHAMP). Can J Cardiol (2008) 1.01
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. J Card Fail (2012) 1.00
Multidisciplinary approaches to the management of high blood pressure. Curr Opin Cardiol (2014) 1.00
Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. Circ Heart Fail (2013) 1.00
Results of a national survey on over-the-counter medicines, Part 1: Pharmacist opinion on current scheduling status. Can Pharm J (Ott) (2012) 0.99
Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations. J Virol (2009) 0.99
Pharmacy 2.0: a scoping review of social media use in pharmacy. Res Social Adm Pharm (2013) 0.98
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int (2008) 0.98
Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Circ Cardiovasc Qual Outcomes (2009) 0.98
Primary health care teams: team members' perceptions of the collaborative process. J Interprof Care (2004) 0.98